{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The complication rate in matched unrelated donor (MUD) allogeneic bone marrow transplant (allo BMT) is known to be high. Graft failure and severe graft versus host disease (GvHD) are the most significant contributors to treatment related mortality (TRM). This treatment regimen will be considered unacceptable if the number of patients that experience TRM is 55% or greater, and effective if TRM is 33% or less.","groups":[{"description":"Our protocol is designed to attempt to improve the current results of MUD allo BMT and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.\n\nPeripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'\n\nperipheral blood lymphocyte therapy: T-cell depletion\n\ncyclophosphamide: T-cell depletion\n\ntacrolimus: T-cell depletion\n\nallogeneic hematopoietic stem cell transplantation: T-cell depletion\n\nperipheral blood stem cell transplantation: T-cell depletion\n\ntotal-body irradiation: T-cell depletion","id":"OG000","title":"T-Cell Depletion Transplant"}],"paramType":"NUMBER","populationDescription":"Patients that received treatment","reportingStatus":"POSTED","timeFrame":"180 days after transplant","title":"Treatment-related Mortality (TRM)","type":"PRIMARY","unitOfMeasure":"participants"}